Cholesterol efflux pathways, inflammation, and atherosclerosis.
TLDR
The causal relationship between plasma HDL-cholesterol levels and CVD has been called into question by Mendelian randomization studies and the majority of clinical trials not showing any benefit of plasma HDL cholesterol raising drugs on CVD as mentioned in this paper.Abstract:
Plasma levels of high-density lipoprotein (HDL) inversely correlate with the incidence of cardiovascular diseases (CVD). The causal relationship between plasma HDL-cholesterol levels and CVD has been called into question by Mendelian randomization studies and the majority of clinical trials not showing any benefit of plasma HDL-cholesterol raising drugs on CVD. Nonetheless, recent Mendelian randomization studies including an increased number of CVD cases compared to earlier studies have confirmed that HDL-cholesterol levels and CVD are causally linked. Moreover, several studies in large population cohorts have shown that the cholesterol efflux capacity of HDL inversely correlates with CVD. Cholesterol efflux pathways exert anti-inflammatory and anti-atherogenic effects by suppressing proliferation of hematopoietic stem and progenitor cells, and inflammation and inflammasome activation in macrophages. Cholesterol efflux pathways also suppress the accumulation of cholesteryl esters in macrophages, i.e. macrophage foam cell formation. Recent single-cell RNASeq studies on atherosclerotic plaques have suggested that macrophage foam cells have lower expression of inflammatory genes than non-foam cells, probably reflecting liver X receptor activation, upregulation of ATP Binding Cassette A1 and G1 cholesterol transporters and suppression of inflammation. However, when these pathways are defective lesional foam cells may become pro-inflammatory.read more
Citations
More filters
Journal ArticleDOI
Dyslipidemia, Diabetes and Atherosclerosis: Role of Inflammation and ROS-Redox-Sensitive Factors.
TL;DR: In this paper, the authors discuss the involvement of dyslipidemia in the progression of atherosclerosis by activating the pro-inflammatory cytokines and oxidative stress-related factors.
Journal ArticleDOI
Exosomes in atherosclerosis: Convergence on macrophages
TL;DR: In this paper , the role of macrophages in atherosclerosis, especially their plasticity and phenotypic and distributional heterogeneity, is summarized and prospected the diagnosis of macophage-associated exosomes, such as imaging agent delivery, biomarkers and therapeutic strategies.
Journal ArticleDOI
Lipid-Laden Macrophages and Inflammation in Atherosclerosis and Cancer: An Integrative View
TL;DR: How the phenotypic and functional plasticity of macrophages allows their multifunctional response to the distinct microenvironments in developing atherosclerotic lesions and in developing malignant tumors is discussed.
Journal ArticleDOI
Mechanistic View on the Effects of SGLT2 Inhibitors on Lipid Metabolism in Diabetic Milieu
TL;DR: In this paper , the authors tried to explain how these drugs could regulate lipid homeostasis and presented the possible involved cellular pathways supported by clinical evidence, which is a major goal for preventing dyslipidemia-induced complications.
Journal ArticleDOI
Macrophages derived from pluripotent stem cells: prospective applications and research gaps
Irina V. Lyadova,A. V. Vasiliev +1 more
TL;DR: In this article , a review systemizes current and prospective iPSC applications and discusses the problem of iMph safety and other issues that need to be explored before IMphs become clinically applicable.
References
More filters
Journal ArticleDOI
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Paul M. Ridker,Brendan M. Everett,Tom Thuren,Jean G. MacFadyen,William Chang,Christie M. Ballantyne,Francisco H. Fonseca,Jose C. Nicolau,Wolfgang Koenig,Stefan D. Anker,John J.P. Kastelein,Jan H. Cornel,Prem Pais,Daniel Pella,Jacques Genest,Renata Cifkova,Alberto J. Lorenzatti,Tamás Forster,Zhanna Kobalava,Luminita Vida-Simiti,Marcus Flather,Hiroaki Shimokawa,Hisao Ogawa,Mikael Dellborg,Paulo Roberto Ferreira Rossi,Roland P.T. Troquay,Peter Libby,Robert J. Glynn +27 more
TL;DR: Antiinflammatory therapy targeting the interleukin‐1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid‐level lowering.
Journal ArticleDOI
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
Paul M. Ridker,Eleanor Danielson,Jacques Genest,Antonio M. Gotto,Wolfgang Koenig,Peter Libby,Alberto J. Lorenzatti,Jean G. MacFadyen,Børge G. Nordestgaard,James Shepherd,James T. Willerson,Robert J. Glynn +11 more
TL;DR: In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events.
Journal ArticleDOI
High density lipoprotein as a protective factor against coronary heart disease: The Framingham study
TL;DR: The major potent lipid risk factor was HDL cholesterol, which had an inverse association with the incidence of coronary heart disease in either men or women and these associations were equally significant even when other lipids and other standard risk factors for coronaryHeart disease were taken into consideration.
Journal ArticleDOI
The plasma lecithin:cholesterol acyltransferase reaction
TL;DR: Several indications exist that the acyltransferase reaction is the major source of plasma esterified cholesterol in man, and one possibility is that it plays a role in the transport of cholesterol from peripheral tissues to the liver.
Journal ArticleDOI
Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths.
Sarah Lewington,Gary Whitlock,Robert Clarke,Paul Sherliker,Jonathan Emberson,Jim Halsey,Nawab Qizilbash,Richard Peto,Rory Collins +8 more
TL;DR: There is conclusive evidence from randomised trials that statins substantially reduce not only coronary event rates but also total stroke rates in patients with a wide range of ages and blood pressures.